Neovacs to Expand Clinical Testing of its TNF-a Kinoid Lead Product Candidate
News Jun 29, 2009
Neovacs has announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-a Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-a inhibitor.
The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE